Quantcast
Last updated on April 17, 2014 at 7:47 EDT

Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook – Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack

July 26, 2013

NEW YORK, July 26, 2013 /PRNewswire/ –

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts’ Corner announced new research reports highlighting C. R. Bard, Inc.
(NYSE: BCR), Centene Corp. (NYSE: CNC), Exact Sciences Corporation (NASDAQ: EXAS),
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), and Merrimack Pharmaceuticals Inc. (NASDAQ:
MACK). Today’s readers may access these reports free of charge – including full price
targets, industry analysis and analyst ratings – via the links below.

C. R. Bard, Inc. Research Report

On July 23, 2013, C. R. Bard, Inc. (Bard) reported its Q2 2013 financial results with
net sales up 2.3% YoY to $759.9 million on a reported basis. Net sales in the US increased
2% YoY to $497.6 million. On the other hand, outside the US, net sales were up 4% YoY to
$262.3 million on a reported and constant currency basis. Net loss was $161.6 million or
$2.03 per diluted share, compared to net income of $133.9 million or $1.54 per diluted
share in Q2 2012. According to Bard, Q2 2013 results include charges of $292.4 million
pre-tax, which relates to estimated costs for product liability matters, net of
recoveries, and other litigation matters. Timothy M. Ring, Chairman and CEO, said, “We
continue to focus on the execution of our investment plan, which we believe will shift the
mix of our portfolio to faster growing products and geographies and contribute to
long-term sustainable leadership positions in our markets.” The Full Research Report on C.
R. Bard, Inc. – including full detailed breakdown, analyst ratings and price targets – is
available to download free of charge at: [

http://www.analystscorner.com/r/full_research_report/141e_BCR]

Centene Corp. Research Report

On July 23, 2013, Centene Corp. (Centene) reported its Q2 2013 financial results.
Premium and Service revenues increased 27.8% YoY to approximately $2.6 billion. Net
earnings attributable to Centene were $39.5 million or $0.70 per diluted share in Q2 2013,
compared to a net loss of $35 million or $0.68 per diluted share in Q2 2012. According to
Centene, diluted EPS for Q2 2013 includes transaction costs of $0.07 per diluted share
associated with AcariaHealth acquisition. Michael F. Neidorff, Centene’s Chairman and CEO,
said, “The solid quarterly results reflect the positive momentum of our focus on
operations and programs that we see continuing for the balance of this year and into
2014.” For full-year 2013, the Company expects Premium and Service revenues to be in the
range of $10.3 billion to $10.6 billion, and diluted EPS to be in the range of $2.65 to
$2.90. The Full Research Report on Centene Corp. – including full detailed breakdown,
analyst ratings and price targets – is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e85d_CNC]

Exact Sciences Corporation Research Report

On July 23, 2013, Exact Sciences Corporation (Exact Sciences) announced its financial
results for Q2 2013. Total revenues were flat at $1.0 million compared to Q2 2012. The
Company reported a net loss of $12.3 million or $0.19 per share in Q2 2013 compared to a
net loss of $14.8 million or $0.26 per share in Q2 2012. Kevin T. Conroy, the Company’s
President and CEO, said, “With the completion of Exact’s submission to the FDA for
Cologuard, our colorectal cancer screening test, the company’s top priorities are
commercial readiness and operational excellence.” The Full Research Report on Exact
Sciences Corporation – including full detailed breakdown, analyst ratings and price
targets – is available to download free of charge at: [

http://www.analystscorner.com/r/full_research_report/9c49_EXAS]

Ironwood Pharmaceuticals, Inc. Research Report

On July 23, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) reported its financial
results for Q2 2013 and also provided an update on its recent business activities. Total
revenues declined 33.8% YoY to approximately $9.7 million. According to Ironwood, revenues
include $6.1 million related to sales of active pharmaceutical ingredient (API), $1.7
million in the amortization of deferred revenue associated with consideration received
from the Company’s collaborations with Astellas and AstraZeneca, and $1.9 million in
milestone payments from Almirall on account of the commercial launches of CONSTELLA in the
UK and Germany. The Company reported a net loss of $65.1 million or $0.57 per share
compared to a net loss of $40.8 million or $0.38 per share in Q2 2012. The Full Research
Report on Ironwood Pharmaceuticals, Inc. – including full detailed breakdown, analyst
ratings and price targets – is available to download free of charge at: [

http://www.analystscorner.com/r/full_research_report/dbc4_IRWD]

Merrimack Pharmaceuticals Inc. Research Report

On July 22, 2013, Merrimack Pharmaceuticals Inc. (Merrimack) announced the enrollment
of its first patient in a Phase 2 clinical trial of its bispecific antibody, MM-111, for
the treatment of advanced gastric, esophageal, and gastroesophageal junction (GEJ)
cancers. According to the Company, the Phase 2 study is unique in the sense that it is
testing MM-111 in two different subsets of patients overexpressing the HER2 (ErB2) cell
surface receptor. The first set of patients traditionally receiving trastuzumab-based
therapy due to their HER2 score of 2+ or 3+ on the Hercep Test and/or positive
fluorescence in situ hybridization status (FISH+). Merrimack reported that these patients
will be randomized to receive either MM-111 combined with paclitaxel and trastuzumab or
paclitaxel and trastuzumab. The second set of patients will not be usually treated with
HER2-targeted therapy because they have a HER2 2+ HercepTest score and have a negative
FISH status (FISH-) for the HER2 gene. They will be randomized to receive either MM-111
combined with paclitaxel or paclitaxel alone. The Full Research Report on Merrimack
Pharmaceuticals Inc. – including full detailed breakdown, analyst ratings and price
targets – is available to download free of charge at: [

http://www.analystscorner.com/r/full_research_report/8bb0_MACK]

—-

EDITOR NOTES:

        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by a CFA. However, we are only human and are prone to make
          mistakes. If you notice any errors or omissions, please notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquiries, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document,
article or report is prepared and authored by Equity News Network. An outsourced research
services provider has, through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according to the Procedures
outlined by Equity News Network. Equity News Network is not entitled to veto or interfere
in the application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the information
provided in this document. This information is not to be construed as personal financial
advice. Readers are encouraged to consult their personal financial advisor before making
any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or shortcoming. No liability is
accepted by Equity News Network whatsoever for any direct, indirect or consequential loss
arising from the use of this document. Equity News Network expressly disclaims any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Equity News Network does not
(1) guarantee the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The included
information is subject to change without notice.

http://AnalystsCorner.com

SOURCE Analysts’ Corner


Source: PR Newswire